Biotech stocks crumbled last year, and many prominent hedge funds have suffered deep losses. But some biotech investors are thriving by focusing on mergers, short selling, and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022 (please see the article" In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners" under the reading folder).

What factors are expected to drive M&A in the biotech space? Which segment of the biotech sector performed well in 2021? Do you think Biotech stocks will be a good investment in 2022? Please discuss.